PGNY vs. AGL, SHC, CERT, NARI, MRUS, TGTX, TWST, IMCR, GDRX, and ACAD
Should you be buying Progyny stock or one of its competitors? The main competitors of Progyny include agilon health (AGL), Sotera Health (SHC), Certara (CERT), Inari Medical (NARI), Merus (MRUS), TG Therapeutics (TGTX), Twist Bioscience (TWST), Immunocore (IMCR), GoodRx (GDRX), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "medical" sector.
agilon health (NYSE:AGL) and Progyny (NASDAQ:PGNY) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, community ranking, media sentiment and institutional ownership.
agilon health has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, Progyny has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.
Progyny has lower revenue, but higher earnings than agilon health. agilon health is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.
Progyny received 38 more outperform votes than agilon health when rated by MarketBeat users. Likewise, 75.00% of users gave Progyny an outperform vote while only 52.13% of users gave agilon health an outperform vote.
In the previous week, Progyny had 4 more articles in the media than agilon health. MarketBeat recorded 9 mentions for Progyny and 5 mentions for agilon health. agilon health's average media sentiment score of 1.26 beat Progyny's score of 0.41 indicating that Progyny is being referred to more favorably in the news media.
Progyny has a net margin of 5.53% compared to Progyny's net margin of -5.67%. agilon health's return on equity of 11.61% beat Progyny's return on equity.
94.9% of Progyny shares are owned by institutional investors. 3.2% of agilon health shares are owned by insiders. Comparatively, 12.3% of Progyny shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
agilon health presently has a consensus price target of $9.25, suggesting a potential upside of 51.39%. Progyny has a consensus price target of $43.11, suggesting a potential upside of 61.65%. Given agilon health's stronger consensus rating and higher probable upside, analysts plainly believe Progyny is more favorable than agilon health.
Summary
Progyny beats agilon health on 17 of the 18 factors compared between the two stocks.
Get Progyny News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
